As a 1p/19q codeletion, MGMT promoter methylation and IDH1 mutation is an important marker for the prognostic evaluation of glioma patients, and we investigated expression of HIC2 and this clinicopathologic feature. Here, HIC2 is linked to central nervous system cancer.